Immutep Limited — Form 20-F Summary
Reporting period: Fiscal year ended June 30, 2023, with comparisons to fiscal 2022 and 2021. This is an annual report, not a 2022 Q4 filing. Financial figures are in Australian dollars (A$) unless stated otherwise. Immutep is a clinical-stage biotechnology company developing LAG-3-based immunotherapies; it had no product approved for commercial sale.
Financial performance and position
| Metric | FY2023 | FY2022 |
|---|---|---|
| License revenue | Nil | A$0.17 million |
| Research material sales | A$0.19 million | A$0.08 million |
| Grant income | A$3.31 million | A$4.46 million |
| Total revenue and other income | A$5.20 million | A$6.76 million |
| Research and development and intellectual property expenses | A$36.26 million | A$31.34 million |
| Corporate administrative expenses | A$8.68 million | A$7.21 million |
| Net loss | A$39.90 million | A$32.21 million |
| Net cash used in operating activities | A$35.36 million | A$30.23 million |
| Cash and cash equivalents at year-end | A$123.42 million | A$80.00 million |
- Revenue remains immaterial and largely non-recurring; grant income, interest, foreign-exchange gains and other items make up much of reported income. No product sales were reported.
- Research and development spending rose about 16% as clinical trial activity expanded, particularly TACTI-003 and AIPAC-003. Net loss increased about 24% year over year.
- Cash increased following a June 2023 capital raise of approximately A$80 million gross. Financing activities provided A$76.02 million net; ordinary shares outstanding increased from 866.2 million to 1,187.3 million during the year.
- Total assets were A$147.45 million and total liabilities A$10.98 million at June 30, 2023. Current assets were A$134.97 million and current liabilities A$9.77 million.
- Carrying value of the convertible note liability was A$0.84 million; lease liabilities were A$0.39 million. The filing reports no material capital commitments or contingent liabilities and no material bank borrowing.
- Operating margin and product gross margin are not meaningful indicators for the company’s current development-stage business; the filing does not provide a clear product-sales basis for calculating them.
Business developments and changes
- Efti (eftilagimod alpha/IMP321): Immutep reported positive Phase II results in first-line non-small-cell lung cancer (NSCLC), including an initial median overall survival of 25.0 months in patients with PD-L1 TPS of at least 1%. The company is preparing a registrational Phase III trial, TACTI-004, after receiving positive FDA feedback on its planned trial. Efti received FDA Fast Track designation for specified first-line NSCLC use.
- TACTI-003, a randomized Phase IIb trial of efti plus pembrolizumab in first-line head and neck cancer, was about 91% enrolled at fiscal year-end. AIPAC-003, an integrated Phase II/III breast cancer trial, began recruiting; its Phase III component remains subject to results, regulatory interactions and available resources.
- Other efti studies include investigator-led trials and collaborations. The filing reports encouraging interim activity in INSIGHT-003, but these are clinical-stage findings, not evidence of regulatory approval or established commercial benefit.
- IMP761: Development for autoimmune disease remained preclinical. The company anticipated starting clinical trials in the first half of 2024, subject to completion of enabling work.
- IMP701 and IMP731 are licensed to Novartis and GSK, respectively, which control their development. GSK had halted a Phase II program for further assessment; Novartis continued to evaluate IMP701.
- Immutep completed a 2,000-liter efti manufacturing run in December 2022. It reported European clinical-trial authorization for material made at that scale in September 2023, after the reporting date.
Outlook, risks and unusual items
- Management estimated that year-end cash would fund operations at least until early 2026, while cautioning that this is a forward-looking estimate. The company expects substantial losses and higher R&D expenses as trials advance and does not expect significant revenue before product approval and commercial sales.
- Key risks include clinical failure or delay, regulatory uncertainty, patient enrollment, reliance on contract manufacturers and other external vendors, partner performance, intellectual-property challenges, competition, and the need for future financing. A shortfall or unfavorable financing could delay, reduce or stop programs; equity financing could dilute shareholders.
- The FY2023 result included A$0.62 million foreign-exchange gain, A$0.13 million non-cash warrant fair-value gain and A$0.94 million interest income. The prior-year licensing milestone revenue did not recur. The remaining 206,507 U.S. warrants expired in January 2023; a convertible note balance remained outstanding.
- The auditor identified grant income as a critical audit matter because recognition depends on judgments about qualifying R&D expenditure and jurisdictional rules. PwC issued unqualified opinions on the financial statements and internal control over financial reporting. Management also reported effective disclosure controls and internal controls as of June 30, 2023.
- The filing reports no material legal proceedings and no dividends paid or expected in the foreseeable future.
Important facts for investors to verify
- Whether TACTI-004 proceeds as planned, including final trial design, initiation timing, enrollment and funding requirements.
- Whether the reported efti efficacy signals are confirmed in controlled, adequately powered trials and translate into regulatory approval and commercial adoption.
- Actual cash burn, grant receipts and runway as trial spending rises; management’s early-2026 estimate is not assured.
- The terms, conversion or repayment status of the remaining convertible notes, and the effect of share-based awards and future capital raises on dilution.
- The timing and results of IMP761 toxicology and clinical-enabling work, plus development decisions by partners for IMP701 and IMP731.